Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: A case–control study

Moghtaderi, Ali; Hashemi, Mohammad; Sharafaddinzadeh, Naser; Dabiri, Soroosh; Moazeni‐Roodi, Abdolkarim; Ramroodi, Noorollah; Zolfaghari, Moloud

doi:10.1016/j.clinbiochem.2011.04.010

Cited by 10 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is fair to underscore that a trend toward lower levels of serum PON-1 activity in MS patients compared to healthy was also reported in other two studies (Ferretti et al 2005;Kirbas et al 2013). In contrast, Moghtaderi et al did not find any significant difference between MS and healthy individuals in a recent work (Moghtaderi et al 2011). …”

Section: ) That Includes Also Individuals With Mixed Vad/load Formmentioning

confidence: 68%

Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases

Castellazzi

Trentini

Romani

et al. 2016

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

High-density lipoprotein (HDL)-bound paraoxonase-1 (PON-1) is mechanistically related to oxidative stress, inflammation and atherosclerosis and this multirole nature positions the enzyme as potential pathogenic player and candidate biomarker for many diseases. Our previous work suggests that decline in serum PON-1 activities, i.e. arylesterase and paraoxonase, might be associated with the occurrence of mild cognitive impairment (MCI) to late onset Alzheimer's disease (LOAD) or vascular dementia (VAD). The present study aimed to: (1) expand our previous findings in a larger and different population, including patients with LOAD-VAD mixed dementia (MD); (2) explore a possible association between PON-1 and multiple sclerosis (MS); (3) evaluate if cerebrospinal fluid (CSF) levels of PON-1 activities might be useful biomarkers for MS. We found that serum arylesterase, but not paraoxonase, levels of PON-1 were significantly lower in patients affected by MCI (n=232), VAD (n=65), LOAD (n=175), MD (n=88) as well as those with MS (n=104) as compared to healthy controls. Notably, the most pronounced decline in this activity was shown by MD (-18%, p<0.01) and MS (-23%, p<0.001), while the lowest changes were detected in the MCI group (11%, p<0.05). Only arylesterase was detectable in the CSF of MS patients and the levels were not significantly different from those detected in the other two neurological control groups. Overall our data suggest that a depressed arylesterase activity could be a common denominator of different neurological diseases which, independently of their peculiar ethiopathogenesis and pathophysiology, appear to be all characterized by an altered systemic redox balance.

show abstract

Section: ) That Includes Also Individuals With Mixed Vad/load Formmentioning

confidence: 68%

Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases

Castellazzi

Trentini

Romani

et al. 2016

The International Journal of Biochemistry & Cell Biology

View full text Add to dashboard Cite

show abstract

“…[114][115][116][117] In this regard a few studies have addressed the possible correlation of PON1 polymorphisms with MS and all coincide in not finding evidence for this type of association. [118][119][120][121] In a longitudinal study, PON1 activity showed no changes in the course of the stable and progressive type of MS and it decreased in the course of MS relapses. 122 …”

Section: Pon1 and Multiple Sclerosismentioning

confidence: 99%

Paraoxonase 1 in neurological disorders

Menini

Gugliucci

2013

Redox Report

View full text Add to dashboard Cite

Paroxonase 1 displays multiple physiological activities that position it as a putative player in the pathogenesis of neurological disorders. Here we reviewed the literature focusing on the role of paraoxonase 1 (PON1) as a factor in the risk of stroke and the major neurodegenerative diseases. PON1 activity is reduced in stroke patients, which significantly correlates inversely with carotid and cerebral atherosclerosis. The presence of the R allele of the Q192R PON1 polymorphism seems to potentiate this risk for stroke. PON1 exerts peroxidase activities that may be important in neurodegenerative disorders associated with oxidative stress. PON1 is also a key detoxifier of organophosphates and organophosphate exposure has been linked to the development of neurological disorders in which acetylcholine plays a significant role. In Parkinson's disease most of the studies suggest no participation of either L55M or the Q192R polymorphisms in its pathogenesis. However, many studies suggest that the MM55 PON1 genotype is associated with a higher risk for Parkinson's disease in individuals exposed to organophosphates. In Alzheimer's disease most studies have failed to find any association between PON1 polymorphisms and the development of the disease. Some studies show that PON1 activity is decreased in patients with Alzheimer's disease or other dementias, suggesting a possible protective role of PON1. No links between PON1 polymorphisms or activity have been found in other neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis. PON1 is a potential player in the pathogenesis of several neurological disorders. More research is warranted to ascertain the precise pathogenic links and the prognostic value of its measurement in neurological patients.

show abstract

“…It suggests that the exacerbation of oxidative stress during the relapse decreases the activity of PON1. In another study published recently, no statistically significant differences were found in PON1 activity between patients with MS in relapse phase ( n = 63) and control group ( n = 63), but the mean values were lower in patients with MS .…”

Section: Introductionmentioning

confidence: 74%

Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy

et al. 2012

View full text Add to dashboard Cite

show abstract

Lack of association between paraoxonase 1 Q192R polymorphism and multiple sclerosis in relapse phase: A case–control study

Cited by 10 publications

References 25 publications

Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases

Decreased arylesterase activity of paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases

Paraoxonase 1 in neurological disorders

Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy

Contact Info

Product

Resources

About